Status
Conditions
Treatments
About
This study evaluates the cardiovascular effects of adding the ketone body 3-hydroxy butyrate (3-OHB) to whey protein during human endotoxemia. Further, this study compares cardiovascular changes during healthy and catabolic conditions.
Participants will receive isocaloric, isonitrogenous beverages of either whey or 3-OHB+whey in a randomized crossover design during either healthy (overnight fast) or catabolic conditions (inflammation/endotoxemia + 36 h fast and bed rest).
Full description
Background: A newly published study found beneficial cardiovascular effects of 3-OHB infusion in a population with chronic heart failure, significantly increasing cardiac output. Similar effects on cardiac output were observed in healthy volunteers. These findings pave the way for 3-OHB as a therapeutic nutritional supplement, since it is well-absorbed during oral consumption. However, it is unknown whether the cardiovascular effects of 3-OHB persist during a sepsis-like catabolic state and when administered orally.
Aim: This study aims to investigate the cardiovascular effects of adding the ketone body 3-hydroxy butyrate (3-OHB) to whey protein during a human disease model, comprising endotoxemia + bed rest + fast.
Hypothesis:
Adding the ketone body 3-OHB to an oral protein supplement increases cardiac output measures
Catabolic stress (endotoxemia/inflammation + 36 h fast and bed rest) induces cardiovascular changes compared with healthy conditions (overnight fast)
Interventions:
In a randomized crossover design, eight healthy, lean, young men will undergo either:
i) Healthy conditions (overnight fast) + whey protein^
ii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest*) + whey protein^
iii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest*) + 3-OHB/whey protein^"
*LPS will be administered (1 ng/kg) the day prior to the study together with fast and bed rest. On the study day LPS (0.5 ng/kg) will be injected.
^Beverages will be isonitrogenous and isocaloric (fat will be added) with 45 g whey protein + 20 g maltodextrin. Bolus/sip administration will be applied (1/3 bolus, 1/2 sip)
" 50 grams of 3-OHB will be orally administered (1/2 bolus, 1/2 sip)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Recent immobilization of an extremity that is not fully rehabilitated
Lactose, lidocain or rubber allergies
Current disease
Use of anabolic steroids
Smoking
Former major abdominal surgery (Or current problems with the GI tract)
•>10 hours of exercise/weak
Present ketogenic diets or high-protein diets
Blood doner that does not want to discontinue blood donations until study completion
Pending MR scan
Primary purpose
Allocation
Interventional model
Masking
8 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal